Biogen (BIIB) Downgraded to Hold at BidaskClub


BIIB has been the subject of a number of other reports. Citigroup dropped their price objective on shares of Biogen from $483.00 to $470.00 and set a buy rating for the company in a report on Monday, October 8th.



from Biotech News